- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07639476
Study on Mental Health Promoting Effects of Natural Psychotherapy for Adolescents (NP-A-MHP)
The Effect of Universal Intervention Based on Natural Psychotherapy: Evidence From Chinese Adolescents
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Objective 1: Evaluate the Efficacy of Natural Psychotherapy on Primary Outcomes (Anxiety Symptoms and Rumination) To evaluate the short-term and sustained efficacy of the Natural Psychotherapy program in reducing anxiety symptoms and maladaptive rumination among primary and middle school students compared to standard schooling.
Objective 2: Assess the Impact on Secondary Outcomes (Psychological Well-being, Emotional Regulation, Stress, Sleep, Self-Esteem, Depression, Life Satisfaction, and Social Support) To assess the effects of the Natural Psychotherapy program on secondary psychological outcomes, including mindfulness, perceived stress, resilience, insomnia severity, self-esteem, depressive symptoms, life satisfaction, eudaimonic well-being, and perceived social support, and to examine whether improvements in these domains mediate the primary outcomes.
Objective 3: Explore the Mechanisms of Change and Predictors of Treatment Response To explore the underlying psychological mechanisms through which Natural Psychotherapy produces its therapeutic effects on primary outcomes (anxiety and rumination) and to identify baseline predictors and moderators of treatment response.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Xiang-Yang Zhang, Ph.D.
- Phone Number: +86-10-62710644
- Email: zhangxy99@mail.tsinghua.edu.cn
Study Contact Backup
- Name: Fangfang Shangguan, Ph.D.
- Phone Number: ++8610-13501000369
- Email: shanggff@cnu.edu.cn
Study Locations
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100037
- Capital Normal University, Beijing
-
Contact:
- Fangfang Shangguan, Ph.D.
- Phone Number: +86-10-62710644
- Email: shanggff@cnu.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Ages: 7 to 18 years.
- Population: School-aged children and adolescents currently enrolled and attending primary or secondary school.
- Capacity: Ability to comprehend the study procedures and provide assent (or consent, if applicable).
Exclusion Criteria:
- School Attendance: Children not currently attending school or on long-term academic leave.
- General Exclusion: Any condition that, in the opinion of the investigator or school physician, would interfere with the participant's ability to attend school or comply with study procedures.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Universal Intervention based on Natural Psychotherapy
Natural psychotherapy is based on "Morita therapy" and is a psychotherapy that fully reflects the characteristics of Chinese culture, taking into account the Chinese cultural background and actual clinical characteristics. Participants will receive a 4-week Multi-model Nature-based Meditation program delivered in regular classrooms. The program consists of weekly group sessions integrating nature-guided imagery exercises with principles of Nature Psychotherapy. Intervention Diary will be collected and will receive response from trained instructors. Sessions are facilitated by trained instructors. |
A 4-week universal group meditation practice delivered in classrooms.
The intervention aims to reduce anxiety and depressive symptoms through nature-based mindfulness exercises.
Participants are required to maintain a daily log of their meditation practice and life events, with a particular focus on instances of emotional fluctuation and their corresponding behavioral responses.
|
|
No Intervention: Standard School Education Control
Participants assigned to this arm will continue with standard school education as usual (business-as-usual) without the meditation intervention
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Generalized Anxiety Disorder-7 Scale (GAD-7)
Time Frame: Week 1, Week 5, Week 9, Week 17, Week 29
|
A 7-item self-report scale assessing the severity of anxiety symptoms over the past two weeks. Scores range from 0 to 21, with higher scores indicating more severe anxiety. Clinical cut-off scores are: 0-4 (minimal/no clinical anxiety), 5-9 (mild), 10-14 (moderate),and≥ 15 (severe). This is a widely used, valid, and reliable tool for screening and monitoring anxiety in adolescents. Time points of measurements: (1) Assessment at Week 1 (Pre-intervention, Baseline); (2) Week 5( immediately Post-intervention, after the 4-week intervention period); (3) Week 9 (1-month follow-up); (4) Week 17 (3-month follow-up); (5) Week 29: 6-month follow-up. |
Week 1, Week 5, Week 9, Week 17, Week 29
|
|
Ruminative Responses Scale (RRS)
Time Frame: Week 1, Week 5, Week 9, Week 17, Week 29
|
Symptom Rumination: Assesses repetitive focus on the symptoms of distress (e.g., feelings of sadness, fatigue, and loneliness). Brooding: Assesses a moody, reflective style characterized by passive comparison of one's current situation with unachieved standards. Reflective Pondering: Assesses purposeful and reflective examination of one's mood and its causes to gain insight. Scoring: Each item is rated on a 4-point Likert scale from 1 (almost never) to 4 (almost always). Total scores range from 22 to 88. Higher total scores indicate a greater tendency toward rumination. Time points of measurements: (1) Assessment at Week 1 (Pre-intervention, Baseline); (2) Week 5( immediately Post-intervention, after the 4-week intervention period); (3) Week 9 (1-month follow-up); (4) Week 17 (3-month follow-up); (5) Week 29: 6-month follow-up. |
Week 1, Week 5, Week 9, Week 17, Week 29
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mindfulness - Mindful Attention Awareness Scale (MAAS)
Time Frame: Week 1, Week 5, Week 9, Week 17, Week 29
|
A 15-item self-report scale measuring dispositional mindfulness.Each item is rated on a 6-point Likert scale from 1 (almost always) to 6 (almost never).
Scoring is computed as the mean of all 15 items, with scores ranging from 1 to 6.Higher scores indicate greater levels of dispositional mindfulness (Brown & Ryan, 2003).Time points of measurements: (1) Assessment at Week 1 (Pre-intervention, Baseline); (2) Week 5( immediately Post-intervention, after the 4-week intervention period); (3) Week 9 (1-month follow-up); (4) Week 17 (3-month follow-up); (5) Week 29: 6-month follow-up.
|
Week 1, Week 5, Week 9, Week 17, Week 29
|
|
Perceived Stress - Perceived Stress Scale (PSS-10)
Time Frame: Week 1, Week 5, Week 9, Week 17, Week 29
|
A 10-item self-report questionnaire measuring perceived stress over the past month.Each item is rated on a 5-point Likert scale from 0 (never) to 4 (very often).
Four positively worded items are reverse-scored.
Total scores range from 0 to 40, with higher scores indicating greater perceived stress.
Interpretive guidelines: 0-13 (low), 14-26 (moderate), 27-40 (high stress) (Cohen et al.,1983).
Time points of measurements: (1) Assessment at Week 1 (Pre-intervention, Baseline); (2) Week 5( immediately Post-intervention, after the 4-week intervention period); (3) Week 9 (1-month follow-up); (4) Week 17 (3-month follow-up); (5) Week 29: 6-month follow-up.
|
Week 1, Week 5, Week 9, Week 17, Week 29
|
|
Resilience - Connor - Davidson Resilience Scale (CD-RISC-10)
Time Frame: Week 1, Week 5, Week 9, Week 17, Week 29
|
A 10-item self-report scale measuring resilience.
Each item is rated on a 5-point Likert scale from 0 (not true at all) to 4 (true nearly all the time).
Total scores range from 0 to 40, with higher scores indicating greater resilience (Campbell-Sills & Stein, 2007).
Time points of measurements: (1) Assessment at Week 1 (Pre-intervention, Baseline); (2) Week 5( immediately Post-intervention, after the 4-week intervention period); (3) Week 9 (1-month follow-up); (4) Week 17 (3-month follow-up); (5) Week 29: 6-month follow-up.
|
Week 1, Week 5, Week 9, Week 17, Week 29
|
|
Insomnia Severity - Insomnia Severity Index (ISI)
Time Frame: Week 1, Week 5, Week 9, Week 17, Week 29
|
A 7-item self-report questionnaire assessing insomnia severity over the past two weeks.
Each item is rated on a 5-point Likert scale from 0 (no problem) to 4 (very severe problem).
Total scores range from 0 to 28,with higher scores indicating more severe insomnia.
Cutoffs: 0-7 (no clinically significant insomnia), 8-14 (subthreshold), 15-21 (moderate), 22-28 (severe) (Bastien et al.,2001).
Time points of measurements: (1) Assessment at Week 1 (Pre-intervention, Baseline); (2) Week 5( immediately Post-intervention, after the 4-week intervention period); (3) Week 9 (1-month follow-up); (4) Week 17 (3-month follow-up); (5) Week 29: 6-month
|
Week 1, Week 5, Week 9, Week 17, Week 29
|
|
Self-Esteem -Rosenberg Self-Esteem Scale (SES)
Time Frame: Week 1, Week 5, Week 9, Week 17, Week 29
|
A 10-item scale measuring global self-worth and self-acceptance.
Each item is rated on a 4-point Likert scale from 1 (strongly agree) to 4 (strongly disagree).
Total scores range from 10 to 40, with higher scores reflecting higher self-esteem.
Time points of measurements: (1) Assessment at Week 1 (Pre-intervention, Baseline); (2) Week 5( immediately Post-intervention, after the 4-week intervention period); (3) Week 9 (1-month follow-up); (4) Week 17 (3-month follow-up); (5) Week 29: 6-month follow-up.
|
Week 1, Week 5, Week 9, Week 17, Week 29
|
|
The Patient Health Questionnaire-9 (PHQ-9)
Time Frame: Week 1, Week 5, Week 9, Week 17, Week 29
|
The PHQ-9 is a brief and efficient self-assessment tool mainly used for screening depressive disorders (Major Depressive Disorder, MDD) and evaluating the severity of depressive symptoms.
It was developed by Kurt Kroenke et al. (2001) and is one of the gold standard tools for screening depression in clinical practice and epidemiological studies.
The questionnaire consists of 9 items and uses 4-point Likert scale from 0 (almost never) to 3 (almost always).
The total score ranges from 0 to 27, with higher scores indicating greater depression.
In this study, only the middle school groups used this questionnaire, while the primary school group did not.
Time points of measurements: (1) Assessment at Week 1 (Pre-intervention, Baseline); (2) Week 5( immediately Post-intervention, after the 4-week intervention period); (3) Week 9 (1-month follow-up); (4) Week 17 (3-month follow-up); (5) Week 29: 6-month follow-up.
|
Week 1, Week 5, Week 9, Week 17, Week 29
|
|
Life Satisfaction
Time Frame: Week 1, Week 5, Week 9, Week 17, Week 29
|
The research team used a self-compiled social survey questionnaire based on the actual situation of Chinese primary and secondary school students.
The questionnaire consists of 6 items and uses a 5-point Likert scale (1 = very scary, 2 = very dissatisfied, 3 = about the same between satisfied and dissatisfied, 4 = very satisfied, 5 = very happy).
The total score ranges from 6 to 30 points, with a higher score indicating a greater satisfaction of the individual with their current life.
Time points of measurements: (1) Assessment at Week 1 (Pre-intervention, Baseline); (2) Week 5( immediately Post-intervention, after the 4-week intervention period); (3) Week 9 (1-month follow-up); (4) Week 17 (3-month follow-up); (5) Week 29: 6-month follow-up.
|
Week 1, Week 5, Week 9, Week 17, Week 29
|
|
Perceived Social Support - Multidimensional Scale of Perceived Social Support (MSPSS)
Time Frame: Week 1, Week 5, Week 9, Week 17, Week 29
|
A 12-item self-report scale assessing perceived social support from family (4 items), friends (4 items), and significant others (4 items).
Each item is rated on a 7-point Likert scale from 1 (very strongly disagree) to 7 (very strongly agree).
Total scores range from 12 to 84, with higher scores indicating greater perceived social support.
Time points of measurements: (1) Assessment at Week 1 (Pre-intervention, Baseline); (2) Week 5( immediately Post-intervention, after the 4-week intervention period); (3) Week 9 (1-month follow-up); (4) Week 17 (3-month follow-up); (5) Week 29: 6-month follow-up.
|
Week 1, Week 5, Week 9, Week 17, Week 29
|
|
Eudaimonic Well-being - Flourishing Scale (FS-8)
Time Frame: Week 1, Week 5, Week 9, Week 17, Week 29
|
A 8-item scale measuring psychological functioning, meaning, and social well-being.
Each item is rated on a 7-point Likert scale from 1 (strongly disagree) to 7 (strongly agree).
Total scores range from 8 to 56,with higher scores indicating greater flourishing.
Time points of measurements: (1) Assessment at Week 1 (Pre-intervention, Baseline); (2) Week 5( immediately Post-intervention, after the 4-week intervention period); (3) Week 9 (1-month follow-up); (4) Week 17 (3-month follow-up); (5) Week 29: 6-month follow-up.
|
Week 1, Week 5, Week 9, Week 17, Week 29
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Positive and Negative Rumination Scale (PANRS)
Time Frame: Week 1, Week 5, Week 9, Week 17, Week 29
|
The aim was to separately explore the positive and negative aspects of rumination.
The scale consists of 23 items and is divided into five factors: enjoying happiness, suppressing happiness, negative attribution, positive coping, and self-denial.
The PANRS uses a 4-point Likert scale from 1 (almost never) to 4 (almost always).
A higher score indicates a more severe tendency towards rumination.
In this study, only the factors of enjoying happiness and positive coping were used.
Time points of measurements: (1) Assessment at Week 1 (Pre-intervention, Baseline); (2) Week 5( immediately Post-intervention, after the 4-week intervention period); (3) Week 9 (1-month follow-up); (4) Week 17 (3-month follow-up); (5) Week 29: 6-month follow-up.
|
Week 1, Week 5, Week 9, Week 17, Week 29
|
|
Executive Function -Self-report Executive Function Scale
Time Frame: Week 1, Week 5, Week 9, Week 17, Week 29
|
Assesses key aspects of executive function such as cognitive flexibility, working memory, and inhibitory control in daily functioning.
In this study, only the cognitive flexibility and working memory dimensions from the scale were used.
Each item is rated on a 3-point Likert scale from 1 (never) to 3 (often).
After reverse scoring, total scores range from 15-45, with higher scores indicating better executive functioning.
Time points of measurements: (1) Assessment at Week 1 (Pre-intervention, Baseline); (2) Week 5( immediately Post-intervention, after the 4-week intervention period); (3) Week 9 (1-month follow-up); (4) Week 17 (3-month follow-up); (5) Week 29: 6-month follow-up.
|
Week 1, Week 5, Week 9, Week 17, Week 29
|
|
Internet Gaming Disorder Risk - Brief Internet Gaming Disorder Scale (IGDS9-SF)
Time Frame: Week 1, Week 5, Week 9, Week 17, Week 29
|
A 9-item self-report scale screening for symptoms of problematic gaming behavior based on DSM-5 criteria.
Each item is rated on a 5-point Likert scale from 1 (never) to 5 (very often).
Total scores range from 9 to 45, with higher scores indicating greater risk of internet gaming disorder.
Time points of measurements: (1) Assessment at Week 1 (Pre-intervention, Baseline); (2) Week 5( immediately Post-intervention, after the 4-week intervention period); (3) Week 9 (1-month follow-up); (4) Week 17 (3-month follow-up); (5) Week 29: 6-month follow-up.
|
Week 1, Week 5, Week 9, Week 17, Week 29
|
|
Non-Suicidal Self-Injury - Adolescent Non-Suicidal Self-Injury Assessment Questionnaire (ANSAQ)
Time Frame: Week 1, Week 5, Week 9, Week 17, Week 29
|
The ANSAQ is a questionnaire assessing frequency, methods, and functions of Non-Suicidal Self-Injury (NSSI) behaviors in adolescents.
Each item is rated on a 5-point Likert scale from 0 (never) to 4 (always).
This study utilized 12 items from the behavioral questionnaire.
Total scores range from 0 to 48, with higher scores indicating more diverse methods or higher frequency of non-suicidal self-injury over the past year.
Includes follow-up questions on context and triggers.
Time points of measurements: (1) Assessment at Week 1 (Pre-intervention, Baseline); (2) Week 5( immediately Post-intervention, after the 4-week intervention period); (3) Week 9 (1-month follow-up); (4) Week 17 (3-month follow-up); (5) Week 29: 6-month follow-up.
|
Week 1, Week 5, Week 9, Week 17, Week 29
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Xiang-Yang Zhang, Ph.D., Tsinghua University
Publications and helpful links
General Publications
- Koivisto, M. , & Grassini, S. . (2022). Mental imagery of nature induces positive psychological effects. Current Psychology, 1-16.
- Chen YQ, Li XR, Zhang L, Zhu WB, Wu YQ, Guan XN, Xiu MH, Zhang XY. Therapeutic Response Is Associated With Antipsychotic-Induced Weight Gain in Drug-Naive First-Episode Patients With Schizophrenia: An 8-Week Prospective Study. J Clin Psychiatry. 2021 May 11;82(3):20m13469. doi: 10.4088/JCP.20m13469.
- Wang DM, Chen DC, Xiu MH, Wang L, Kosten TR, Zhang XY. A double-blind, randomized controlled study of the effects of celecoxib on clinical symptoms and cognitive impairment in patients with drug-naive first episode schizophrenia: pharmacogenetic impact of cyclooxygenase-2 functional polymorphisms. Neuropsychopharmacology. 2024 Apr;49(5):893-902. doi: 10.1038/s41386-023-01760-8. Epub 2023 Oct 30.
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CNU-202601001 (Other Identifier: Capital Normal University)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.